Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase ii trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT)

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4439-4443

  Wöll, Ewald ^a   Greil, Richard ^b   Eisterer, Wolfgang ^c   Bechter, Oliver ^c   Fridrik, Michael A ^d   Grünberger, Birgit ^e   Zabernigg, August ^f   Mayrbäurl, Beate ^g   Russ, Gudrun ^b   Dlaska, Margit ^c   Obrist, Peter ^h   Thaler, Josef ^g  

^a St Vinzenz Hospital Zams   (Austria)

^b III Medizinische Universitätsklinik   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d KEPLER UNIVERSITY HOSPITAL   (Austria)

^e KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^f Kufstein Hospital   (Austria)

^g Klinikum Wels Grieskirchen GmbH   (Austria)

^h Institut für Pathologie   (Austria)

Author keywords

Cetuximab; Gastric cancer; Irinotecan; KRAS phase II trial; Oxaliplatin

Indexed keywords

ATROPINE; CETUXIMAB; IRINOTECAN; K RAS PROTEIN; LOPERAMIDE; OXALIPLATIN;

ACNE; ADULT; ADVANCED CANCER; ADVANCED GASTRIC CANCER; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANTICHOLINERGIC SYNDROME; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLON DISEASE; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; REMISSION; SENSORY NEUROPATHY; SKIN TOXICITY; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84855180351     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24(18): 2903-2909, 2006. (Pubitemid 46630593)
2. Wöll E, Devries A, Eisterer W, Hejna M, Keil F, Stein H et al: Chemotherapy in gastric cancer. Anticancer Res 28(2B): 1213-9, 2008. (Pubitemid 351605984)
3. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24(31): 4991-4997, 2006. (Pubitemid 46631401)
4. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1): 36-46, 2008.
5. Wöll E, Kuhr T, Eisterer W, Gattringer K, Greil R, Zabernigg A et al: Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. A first-line multicenter phase II trial of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT). Anticancer Res 28(5B): 2901-2905, 2008.
6. Mendelsohn J and Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21(14): 2787-2799, 2003. (Pubitemid 46606324)
7. Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T et al: Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-ERBB-2 in human gastric cancer. Cancer 75(6 Suppl): 1418-1425, 1995.
8. Aoyagi K, Kohfuji K, Yano S, Murakami N, Miyagi M, Takeda J et al: Evaluation of the epidermal growth factor receptor (EGFR) and c-ERBB-2 in superspreading-type and penetrating-type gastric carcinoma. Kurame Med J 48(3): 197-200, 2001. (Pubitemid 33607408)
9. Takehana T, Kunitomo K, Suzuki S, Kono K, Fujii H, Matsumoto Y et al: Expression of epidermal growth factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol 1(6): 438-445, 2003. (Pubitemid 37413607)
10. Waksal HW: Role of an anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev 18(4): 427-36, 1999.
11. Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS et al: Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 100(2): 298-304, 2009.
12. Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C et al: Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18(3): 510-517, 2007. (Pubitemid 46359631)
13. Casadei R, Rega D, Pinto C, Monari F, Ricci C, Sciannamea G et al: Treatment of advanced gastric cancer with cetuximab plus chemotherapy followed by surgery. Report of a case. Tumori 95(6): 811-814, 2009.
14. Kim C, Lee JL, Ryu MH, Chang HM, Kim TW, Lim HY, Kang HJ, Park YS, Ryoo BY and Kang YK: A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs 29(2): 366-373. Epub 2009 Dec 9., 2011
15. Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Wöll E et al: Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 102(3): 500-505, 2010.
16. Kotoula VCE, Biesmans B, Malousi A, Vrettou E, Fountzilas G and Karkavelas G: Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real-Time Diagnostic. PLoS Genet 4(11): 1-13, 2009.
17. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F and Laurent-Puig P: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26(3): 374-379, 2008. (Pubitemid 351171687)
18. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47(1): 207-214, 1981. (Pubitemid 11167383)
19. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4): 337-345, 2004. (Pubitemid 38944402)
20. Luo HY, Wei W, Shi YX, Chen XQ, Li YH, Wang F et al: Cetuximab enhances the effect of oxaliplatin on hypoxic gastric cancer cell lines. Oncol Rep 23(6): 1735-1745, 2010.
21. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC et al: K-RAS mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359(17): 1757-1765, 2008.